JUNE 1, 2016
Glytec presents key studies at the AACE 25th Annual Scientific and Clinical Congress
Experts demonstrate the ability of automated glucose management to significantly reduce rates of hypoglycemia and DKA.
Waltham, MA — Glytec, the pioneer and leader in providing innovative, FDA cleared glucose management software solutions, today announced that two abstracts addressing the approach to care for patients suffering from hypoglycemia and diabetic ketoacidosis (DKA) were presented at the American Association of Clinical Endocrinologists (AACE) 25th Annual Scientific and Clinical Congress, held from May 25-29th in Orlando, Florida.
The conference showcases the most up-to-date and innovative studies in the endocrinology space, and provides an opportunity for clinicians to network and share best practices.
“Each year AACE welcomes the best of the best in endocrinology, and we are honored to have our research, which demonstrates that the use of automated solutions like our eGMS® are superior to paper protocols for insulin management, selected,” said Glytec’s Chief Medical Officer, Andrew S. Rhinehart, MD, FACP, FACE, CDE, BC-ADM, CDTC. “The study results illustrate the need for providers to rethink how they are treating patients with diabetes and those suffering from any glycemic event in order to enhance population management and overall care quality.”
To showcase the effectiveness of Glytec’s electronic glycemic management system (eGMS®) in the treatment of hypoglycemia and DKA, the following scientific posters were presented at the conference by industry thought leaders, including: Joseph Aloi, MD, Chief, Section of Endocrinology and Metabolism at Wake Forest Baptist Medical Center; Jagdeesh Ullal, MD, MS, CCD, ECNU, FACE, FACP, Assistant Professor, EVMS Strelitz Diabetes Center; Bruce Bode, MD, FACE, Guillermo E. Umpierrez, MD, of Emory University and Paul Chidester, MD, Vice President of Medical Affairs at Sentara Healthcare:
- Improved Inpatient Hypoglycemia Rates with Electronic Glycemic Management System (Poster #1306)
This study compares hypoglycemia rates of 58,686 patients managed either on Glytec’s eGMS, or managed by usual care. The results show that patients managed on eGMS had a lower prevalence of hypoglycemic events and lower average blood glucose compared to usual diabetes care. The findings demonstrate that it may be easier to achieve glycemic targets safely using eGMS intravenous and subcutaneous insulin algorithms for patients in the hospital setting.
- Comparison of Computer-Guided Versus Standard Insulin Infusion Regimens In Patients With Diabetic Ketoacidosis (Poster #1302)
This was a retrospective multicenter study comprised of 2,665 patients with DKA. It compared the treatment of these patients with either a computer-guided program using Glytec’s Glucommander, or standard protocols, such as continuous insulin infusion (CII). The data suggests the use of Glucommander as a component of DKA management is associated with significantly less hypoglycemia, faster time to normalization of blood glucose (< 200 mg/dl) and bicarbonate (< 18 mmol/l) than standard orders for treatment of DKA.
“These studies demonstrate how an automated approach leveraging patient data from an electronic health record can reduce rates of hypoglycemia versus standard insulin infusion regimens,” said Dr. Joseph Aloi, Chief, Section of Endocrinology and Metabolism at Wake Forest Baptist.
Glytec and its research affiliates from Wake Forest Baptist Medical Center and Sentara Healthcare will also be presenting five posters about diabetes management across the continuum of care at the American Diabetes Association 76th Scientific Sessions taking place June 10-14th in New Orleans, Louisiana.
Founded in 2006, Glytec is a rapidly growing clinical information technology company specializing in integrated inpatient and outpatient software and services solutions for diabetes care, with the mission of improving medication management and glycemic control from hospital to home. eGMS®, Glytec’s cloud-based glycemic therapy management software system enables providers, payers and patients to significantly reduce the frequency, risks and costs of hyperglycemia and hypoglycemia. The modular eGMS® centers on the Glucommander suite of FDA-cleared, complex proprietary dosing algorithms for intravenous and subcutaneous insulin dosing. The management of patients requiring insulin therapy is furthered by seamless EHR and connected device integration (SmartClick), robust analytics (GlucoMetrics) and surveillance capabilities (GlucoSurveillance). eGMS® interventional clinical decision support tools allow providers to standardize processes and personalize treatment across all areas of care, and is proven to result in significant improvements in clinical and financial outcomes versus traditional methods. For more information, please visit www.glytecsystems.com.